Study of QLF4113 for men with advanced prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This trial tests an investigational drug called QLF4113 for men with metastatic castration-resistant prostate cancer (mCRPC) that has not responded to standard treatments. The goal is to see if QLF4113 can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a man aged 18 or older.
- You have prostate cancer that has spread and is castration-resistant (mCRPC).
- You have tried standard treatments but they no longer work or you cannot tolerate them.
- You are generally able to care for yourself (ECOG score 0-1).
- You have not had treatment with drugs targeting CD3 or CD2 before.
- You do not have significant heart, lung, liver, or uncontrolled infection issues.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new investigational medicine for prostate cancer that has spread and is no longer controlled by standard hormone therapy. The drug may work by targeting a protein on cancer cells, and the trial will check if it can shrink the cancer or slow its growth.
This trial tests an experimental drug, GLR2037, for men with advanced prostate cancer that has spread to the bones or soft tissue and has progressed despite prior treatments. The drug may help slow the cancer's growth.
This trial tests a new drug, SHR-4394, for men with prostate cancer that has spread to other parts of the body and is no longer responding to current treatments. The goal is to see if this drug can help slow down the cancer.
This trial tests a new radioactive drug called 225Ac-LNC1011 for men with a specific type of advanced prostate cancer that has spread and no longer responds to standard hormone therapy. The goal is to see if it can shrink tumors or slow the disease.
This trial tests two new drugs (QLC5508 and QLH12016) alone or together with other treatments for prostate cancer that has spread to other parts of the body. It may be an option if standard treatments have stopped working or caused side effects.
This trial tests a new drug called QLS2401 for patients with advanced prostate cancer that has spread and no longer responds to standard treatments. The goal is to see if it can help control the cancer.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.